Safeguarding Patient Welfare: Who's In Charge?
@article{Henney2006SafeguardingPW, title={Safeguarding Patient Welfare: Who's In Charge?}, author={J. Henney}, journal={Annals of Internal Medicine}, year={2006}, volume={145}, pages={305-307} }
Over the course of my career, I have been privileged to serve in a variety of roles, including that of oncologist, principal investigator, study manager, senior academic administrator, Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA), and as board member for 3 Fortune 500 and Global 500 companies (AstraZeneca PLC, 2001 to present; AmerisourceBergen Corporation, 2002 to present; and Cigna Corporation, 2004 to present). I have been regulated and a regulator, and I… CONTINUE READING
Topics from this paper
8 Citations
Evaluating Off-Label Uses of Anticancer Drugs: Time for a Change
- Medicine
- Annals of Internal Medicine
- 2009
- 13
Sorrell v. IMS Health: issues and opportunities for informaticians
- Medicine, Computer Science
- J. Am. Medical Informatics Assoc.
- 2013
- 5
- PDF
Pharmaceutical promotion to physicians and First Amendment rights.
- Medicine
- The New England journal of medicine
- 2008
- 30
- PDF
Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints
- Medicine
- PLoS medicine
- 2011
- 85
- PDF
Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug Use
- Medicine
- PloS one
- 2008
- 57
- PDF
L'expansion des indications : médecins, attention
- Medicine
- Canadian Medical Association Journal
- 2007
- 2
- PDF
References
SHOWING 1-6 OF 6 REFERENCES
Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
- Medicine
- Annals of Internal Medicine
- 2006
- 284
- Highly Influential
- PDF
Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school's approach.
- Medicine
- Academic medicine : journal of the Association of American Medical Colleges
- 2006
- 48
- PDF
New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation.
- Medicine
- Health affairs
- 2005
- 40
- PDF
Shalala, 130 F.Supp
- (D. DC
- 2001